AI and quantum physics platform for accelerated drug discovery and development
XtalPi operates a closed-loop drug discovery platform that integrates computational chemistry (quantum physics, AI, cloud supercomputing) with wet-lab automation and robotic systems. The hiring mix—sales-heavy with leadership gaps in science and marketing—signals a company in transition from research mode toward commercialization and geographic expansion (China, UK, US). Active projects in lab automation and efficiency improvements reflect internal friction around streamlining workflows across both dry-lab and wet-lab operations.
Notable leadership hires: Chief Scientific Officer, Head of Marketing
XtalPi is a drug R&D company based in Cambridge, Massachusetts, with operations in China and the United States. The core platform combines quantum physics-based computational tools (VASP, Gaussian, GROMACS, LAMMPS) with wet-lab automation (Beckhoff TwinCAT, Siemens PLC, LabVIEW) in a feedback loop designed to accelerate drug discovery. The company sells to pharmaceutical and biotech organizations seeking faster, more scalable alternatives to traditional discovery workflows. With 501–1,000 employees and active hiring across sales, research, and engineering, the company is expanding into North America, the UK, and Europe.
XtalPi combines quantum physics simulations (VASP, Gaussian, GROMACS, LAMMPS), cloud supercomputing, and AI with wet-lab automation (LabVIEW, Beckhoff TwinCAT, Siemens PLC) in a closed-loop system where computational insights drive lab experiments and lab data improves dry-lab calculations.
XtalPi operates in China and the United States and is actively hiring in all three countries: China, the United Kingdom, and the United States, with strategic focus on expanding footprint in North America and Europe.
Other companies in the same industry, closest in size